Newegg Files for IPO: What's Behind Their $2 Billion in Sales? [View article]
agree'd, old article, but newegg is superior compared to amazon. im surprised to see their numbers are so little, and profit margin so low! the margin concerns me as a potential investor. but as a fan i'd buy a good chunk of them to offset my purchases through them annually. they do provide an easy filter system, best prices, and terrific customer service.
Holiday Cheer: Cel-Sci Should Have Good News [View article]
VFC, please comment on ABIO
this is a multi bagger for sure, great treatment for heart failure, was originally declined due to bad trial design (goofed up internally).
replaced management.
now their product has been Fast Tracked. that speaks volume, as their trial DID show awesome results, but it was the design failure that left out key statistics.
although its not going to get approval for at least another year, the potential is huge.
Oncothyreon and OncoGenex: Room to Rise [View article]
checkout KVA generic pharma mfg, huge rise lately with news on the horizon, probably a approval to continue mfg, do your own dd but i see a 5 bagger in short order.
GLTA. i try and stay away from these R&D based investments. generics is the way to go (i.e. CPD)
Cytori Therapeutics' Cardiac Celution: Encouraging Interim Data [View article]
You spelled wound wrong first paragraph. Otherwise thanks for the in depth read, i look forward to the emerging leaders in step cell therapy. it will put current biotech science into old school industry.
Will Insmed's IPLEX Meet Expectations? [View article]
yes IPLEX will meet and beat expectations.
in fact there are several indications you failed to mention, you should do mor DD and write a follow up article within the week to really portray INSM value.
Pending Clinical Trial Results: Ten Extreme Trades [View article]
INSM is the only one out of those that is a real winner:
-cash flow neutral -zero debt -130m cash -phase IIb data to be released any day now --already has positive results from prior clinical trials ---life threatening disease ALS and MMD means p2b results will approve drug
this is a real sleeper, dont miss out, less then 4 weeks.
Sort by:
Latest | Highest ratedNewegg Files for IPO: What's Behind Their $2 Billion in Sales? [View article]
Holiday Cheer: Cel-Sci Should Have Good News [View article]
this is a multi bagger for sure, great treatment for heart failure, was originally declined due to bad trial design (goofed up internally).
replaced management.
now their product has been Fast Tracked. that speaks volume, as their trial DID show awesome results, but it was the design failure that left out key statistics.
although its not going to get approval for at least another year, the potential is huge.
CytRx Corporation: Key Developments Ahead [View article]
wow ME stooped to an all time low, sounds like you do your DD on message boards haha.
Spectrum Pharma: Zevalin Has Blockbuster Potential [View article]
Oncothyreon and OncoGenex: Room to Rise [View article]
GLTA. i try and stay away from these R&D based investments. generics is the way to go (i.e. CPD)
BioMed News Bytes: Dendreon, Chelsea, Cytori, Cephalon, OraSure, Genzyme, Lixte [View article]
Cytori Therapeutics' Cardiac Celution: Encouraging Interim Data [View article]
Citigroup Advertises 'FDIC-Insured' Forex Daytrading Accounts [View article]
-god bless america lol
CryoCell Has a Future to Bank On [View article]
250%+/ytd though.
BioDelivery Science: A Buy I Couldn't Refuse [View article]
(sites super slow or i'd be more then willing to look back at your previous articles).
Spectrum Pharmaceuticals: Rumors of Buyout Talks Persist [View article]
opinion on CPD and recent price movement?
FDA Calendar: 18 Hot Summer Trades [View article]
7 Small Cap Stock Briefs [View article]
titan is going to be great, 2 or 3 bagger for sure within next couple months.
checkout KV.A, and INSM this week!
Will Insmed's IPLEX Meet Expectations? [View article]
in fact there are several indications you failed to mention, you should do mor DD and write a follow up article within the week to really portray INSM value.
Pending Clinical Trial Results: Ten Extreme Trades [View article]
-cash flow neutral
-zero debt
-130m cash
-phase IIb data to be released any day now
--already has positive results from prior clinical trials
---life threatening disease ALS and MMD means p2b results will approve drug
this is a real sleeper, dont miss out, less then 4 weeks.